Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

K, Squires; A, Lazzarin; JM, Gatell; WG, Powderly; V, Pokrovskiy; JF, Delfraissy; J, Jemsek; A, Rivero; W, Rozenbaum; S, Schrader; M, Sension; A, Vibhagool; A, Thiry; M, Giordano

doi:10.1097/00126334-200408150-00003

Public

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Shared by NobleBlocks on Aug 1, 2004 • 12:00 AM UTC

Authors:

Squires K

Lazzarin A

Gatell JM

Abstract

Background Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia.Methods A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and ...

Discussions